Navigation Links
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Date:9/23/2008

ndolol, we are taking a major step forward in our quest to bring the benefits of personalized medicine to cardiovascular disease," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "We look forward to working with the FDA to make bucindolol available to physicians and patients. We are also working with our partner, LabCorp of America, to develop and introduce a companion genetic test."

In the genetic sub-study of the BEST trial, researchers categorized patients into three groups based on receptor genotype: very favorable, favorable and unfavorable. Patients with the very favorable genotype experienced significant improvements in clinical endpoints compared to placebo, including reductions in all cause mortality, all cause mortality or transplant, cardiovascular mortality, heart failure hospitalization, and cardiovascular hospitalization. While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefited from treatment with bucindolol. Bucindolol also demonstrated clinically significant improvements in ischemic endpoints including reducing the risk of myocardial infarction. Patients with the unfavorable genotype, approximately 10 percent of the study population, did not respond to bucindolol therapy.

About Beta Blockers

The use of beta blockers is the standard of care in patients with heart failure and left ventricular dysfunction, according to clinical practice guidelines of the Heart Failure Society of America (HFSA), the American Heart Association, and the American College of Cardiology. HFSA guidelines state: "Beta-blocker therapy remains a major advance in the treatment of patients with LV systolic dysfunction. Along with ACE inhibitors, this class of drug is now established as routine therapy in patients with LV systolic dysfunction."

About Heart Failure

Heart failure is a chronic and progressive condition in which the heart c
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. FDA Accepts Immucors Response to Warning Letter
9. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... OMICS Group International invites researchers, ... in the ‘Open Access Week’ by actively contributing ... Group Pharma Journals from 20-26th October, 2014. ... emerging Sciences, accelerating with a tremendous speed to ... globe. The industry is gearing with innovation and ...
(Date:9/18/2014)... new microscopy technology that allows them to view ... , Dubbed "Complementation Activated Light Microscopy" (CALM), the ... order of magnitude finer than conventional optical microscopy, ... at the nanometer scale. , In a paper ... , the researchers behind CALM used it to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 September 24 ... City, MX. ASEA is the manufacturer of the world's ... skin care product, RENU28. , The Mexico City ... President Duvan Botero, and ASEA Field Leader Shawn Catmull ... a PhD in Atomic/Medical Physics from the University of ...
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2
... Bavituximab, Currently in Phase II Cancer Trials in Combination with ... Chemotherapy -, ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ...
... design offers enhanced convenience, ease-of-use, and helps optimize ... ... March 3 Metrex Research Corporation is,pleased to announce the newest ... unique patented design offers a new,easy-open/easy-close pull tab with slim, flexible ...
... Disposables, Services and Accessories Revenue Up 102% ... ST. LOUIS, March 3 Stereotaxis, Inc. (Nasdaq:,STXS) ... full year,ended December 31, 2007., For the full ... $27.2 million in 2006. Sales of the Niobe(TM) system ...
Cached Biology Technology:Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 2Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 4Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 5CaviWipes(R): Taking Surface Disinfection to a New Level 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:9/18/2014)... small, icy moon of Uranus, is one of the ... system. Despite its relatively small size, Miranda appears to ... in the formation of at least three remarkable and ... , These coronae are visible in Miranda,s southern hemisphere, ... Arden corona, the largest, has ridges and troughs with ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... For the first time, a study by researchers at Columbia ... post-traumatic stress disorder (PTSD) among adults. The study of male ... the association between asthma and PTSD is not primarily explained ... twin pairs, who had lived together in childhood, and who ...
... N.Y. Single-molecule biologythe revolutionary field that deals ... Tremendous technical advances have made it possible to ... images as they twist, twirl, wobble, and unfold. ... book that was just released by Cold Spring Harbor ...
... MADISON - When University of Wisconsin-Madison researchers succeeded in ... they also began to redefine the political and ethical ... Alta Charo, a UW-Madison professor of law and bioethics, ... the social dimensions of the ongoing controversy over embryonic ...
Cached Biology News:Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study 2New book presents methods to poke and prod individual molecules 2Reprogramming the debate: stem-cell finding alters ethical controversy 2Reprogramming the debate: stem-cell finding alters ethical controversy 3
... Immunogen: Synthetic peptide derived from an ... mTOR (Mammalian target of rapamycin FRAP RAFT1 ... mTOR protein. On Western blots it ... Reactivity: Human (positive control: HEK293 cell ...
MW5...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: